{"id":59971,"date":"2026-03-19T14:07:01","date_gmt":"2026-03-19T06:07:01","guid":{"rendered":"https:\/\/flcube.com\/?p=59971"},"modified":"2026-03-19T14:07:01","modified_gmt":"2026-03-19T06:07:01","slug":"viva-biotech-partners-with-nvidia-to-optimize-ai-drug-design-proteina-complexa-model-targets-actriia-mini-binders","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59971","title":{"rendered":"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders"},"content":{"rendered":"\n<p><strong>Viva Biotech Holdings<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1873:HKG\">HKG: 1873<\/a>) has entered into a <strong>strategic partnership<\/strong> with <strong>NVIDIA Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVDA:NASDAQ\">NASDAQ: NVDA<\/a>) to <strong>optimize the Proteina Complexa model<\/strong>, advancing <strong>AI\u2011driven design of mini\u2011binders targeting ActRIIA<\/strong> \u2013 a collaboration showcasing Viva Bio&#8217;s integrated <strong>&#8220;dry lab\u2011wet lab closed\u2011loop&#8221;<\/strong> R&amp;D platform at the intersection of computational biology and high\u2011throughput protein engineering.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-overview\">Partnership Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Viva Biotech (HKG: 1873) + NVIDIA (NASDAQ: NVDA)<\/td><\/tr><tr><td><strong>Collaboration Focus<\/strong><\/td><td>Optimization of <strong>Proteina Complexa model<\/strong><\/td><\/tr><tr><td><strong>Therapeutic Target<\/strong><\/td><td><strong>ActRIIA<\/strong> (Activin Receptor Type IIA) \u2013 TGF\u2011\u03b2 superfamily member<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Design of <strong>mini\u2011binders<\/strong> (compact protein therapeutics)<\/td><\/tr><tr><td><strong>Core Technology<\/strong><\/td><td>AI\u2011enabled computational design + high\u2011throughput protein production<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-viva-bio-s-integrated-r-amp-d-platform\">Viva Bio&#8217;s Integrated R&amp;D Platform<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Function<\/th><th>Strategic Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Dry Lab (Computational)<\/strong><\/td><td><strong>De novo AI design<\/strong> \u2013 sequence screening, structure prediction, binding affinity modeling<\/td><td>NVIDIA GPU acceleration for Proteina Complexa model refinement<\/td><\/tr><tr><td><strong>Wet Lab (Experimental)<\/strong><\/td><td><strong>High\u2011throughput protein production<\/strong> + <strong>biophysical evaluation<\/strong><\/td><td>Rapid iteration; empirical validation of computational predictions<\/td><\/tr><tr><td><strong>Closed\u2011Loop Integration<\/strong><\/td><td>AI feedback drives experimental design; experimental data refines AI models<\/td><td>Accelerated binder optimization vs. traditional linear R&amp;D workflows<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technical-achievement-amp-ai-enhancement\">Technical Achievement &amp; AI Enhancement<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI\u2011Driven Sequence Screening:<\/strong> Viva Bio leveraged proprietary <strong>AI capabilities<\/strong> to screen mini\u2011binder sequences and provide <strong>feedback to refine original Proteina Complexa model<\/strong><\/li>\n\n\n\n<li><strong>Iterative Optimization:<\/strong><\/li>\n\n\n\n<li>Computational design \u2192 high\u2011throughput production \u2192 biophysical characterization \u2192 model refinement<\/li>\n\n\n\n<li><strong>Result:<\/strong> Significant enhancement in <strong>design efficiency<\/strong> and <strong>target specificity<\/strong> for ActRIIA mini\u2011binders<\/li>\n\n\n\n<li><strong>NVIDIA Collaboration Value:<\/strong> GPU\u2011accelerated computing infrastructure for complex protein\u2011protein interaction modeling and generative AI\u2011based de novo protein design<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-scientific-context-amp-strategic-positioning\">Scientific Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>ActRIIA Biology<\/th><th>Mini\u2011Binder Therapeutic Potential<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Function<\/strong><\/td><td>Key regulator of <strong>muscle growth, bone density, metabolic homeostasis<\/strong>; implicated in <strong>muscle wasting disorders, osteoporosis, obesity<\/strong><\/td><td>Broad therapeutic applicability across metabolic and musculoskeletal diseases<\/td><\/tr><tr><td><strong>Traditional Biologics Limitations<\/strong><\/td><td>Full\u2011length antibodies large, complex manufacturing, limited tissue penetration<\/td><td><strong>Mini\u2011binders<\/strong> \u2013 compact, stable, potentially oral bioavailable, lower production costs<\/td><\/tr><tr><td><strong>Design Challenge<\/strong><\/td><td>Achieving high affinity\/specificity with minimal protein scaffold<\/td><td>AI\u2011enabled de novo design + closed\u2011loop validation addresses historical optimization bottlenecks<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI\u2011Drug Design Market Dynamics:<\/strong> Global AI\u2011enabled drug discovery market projected to exceed <strong>US$9 billion by 2030<\/strong>; protein engineering (de novo binders, enzymes) represents fastest\u2011growing segment driven by biologics complexity and manufacturing cost pressures.<\/li>\n\n\n\n<li><strong>Viva Bio Differentiation:<\/strong> &#8220;Dry lab\u2011wet lab closed\u2011loop&#8221; model distinguishes from pure\u2011play AI companies (limited experimental validation) and traditional CROs (lacking computational capabilities); NVIDIA partnership validates platform sophistication for marquee tech collaborations.<\/li>\n\n\n\n<li><strong>NVIDIA Healthcare Strategy:<\/strong> Collaboration aligns with NVIDIA&#8217;s <strong>BioNeMo<\/strong> and <strong>Clara<\/strong> platform expansion into pharmaceutical applications; GPU computing demand from protein design workflows represents <strong>US$500+ million<\/strong> annual addressable market for NVIDIA&#8217;s data center segment.<\/li>\n\n\n\n<li><strong>ActRIIA Commercial Potential:<\/strong> Successful mini\u2011binder development could target <strong>muscle atrophy<\/strong> (cancer cachexia, sarcopenia), <strong>osteoporosis<\/strong>, and <strong>metabolic disorders<\/strong> \u2013 combined market opportunity exceeding <strong>US$15 billion<\/strong> annually; partnership positions Viva Bio for milestone\/royalty participation or spin\u2011out therapeutic entity.<\/li>\n\n\n\n<li><strong>CRO Industry Evolution:<\/strong> AI\u2011integrated &#8220;hybrid&#8221; CRO model (Viva Bio, Schr\u00f6dinger, Recursion) capturing market share from traditional service\u2011only providers; NVIDIA collaboration enhances Viva Bio&#8217;s competitive positioning for biotech partnerships requiring computational + experimental capabilities.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding partnership outcomes, mini\u2011binder development timelines, and market positioning for AI\u2011enabled protein design. Actual results may differ due to scientific validation challenges, target biology complexity, and competitive dynamics in computational drug discovery.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,1353,1352],"class_list":["post-59971","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ai","tag-hkg-1873","tag-viva-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ: NVDA) to optimize the Proteina Complexa model, advancing AI\u2011driven design of mini\u2011binders targeting ActRIIA \u2013 a collaboration showcasing Viva Bio&#039;s integrated &quot;dry lab\u2011wet lab closed\u2011loop&quot; R&amp;D platform at the intersection of computational biology and high\u2011throughput protein engineering.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59971\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders\" \/>\n<meta property=\"og:description\" content=\"Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ: NVDA) to optimize the Proteina Complexa model, advancing AI\u2011driven design of mini\u2011binders targeting ActRIIA \u2013 a collaboration showcasing Viva Bio&#039;s integrated &quot;dry lab\u2011wet lab closed\u2011loop&quot; R&amp;D platform at the intersection of computational biology and high\u2011throughput protein engineering.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59971\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-19T06:07:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59971#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59971\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders\",\"datePublished\":\"2026-03-19T06:07:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59971\"},\"wordCount\":579,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"HKG: 1873\",\"VIVA Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59971#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59971\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59971\",\"name\":\"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-19T06:07:01+00:00\",\"description\":\"Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ: NVDA) to optimize the Proteina Complexa model, advancing AI\u2011driven design of mini\u2011binders targeting ActRIIA \u2013 a collaboration showcasing Viva Bio's integrated \\\"dry lab\u2011wet lab closed\u2011loop\\\" R&D platform at the intersection of computational biology and high\u2011throughput protein engineering.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59971#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59971\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59971#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders - Insight, China&#039;s Pharmaceutical Industry","description":"Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ: NVDA) to optimize the Proteina Complexa model, advancing AI\u2011driven design of mini\u2011binders targeting ActRIIA \u2013 a collaboration showcasing Viva Bio's integrated \"dry lab\u2011wet lab closed\u2011loop\" R&D platform at the intersection of computational biology and high\u2011throughput protein engineering.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59971","og_locale":"en_US","og_type":"article","og_title":"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders","og_description":"Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ: NVDA) to optimize the Proteina Complexa model, advancing AI\u2011driven design of mini\u2011binders targeting ActRIIA \u2013 a collaboration showcasing Viva Bio's integrated \"dry lab\u2011wet lab closed\u2011loop\" R&D platform at the intersection of computational biology and high\u2011throughput protein engineering.","og_url":"https:\/\/flcube.com\/?p=59971","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-19T06:07:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59971#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59971"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders","datePublished":"2026-03-19T06:07:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59971"},"wordCount":579,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","HKG: 1873","VIVA Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59971#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59971","url":"https:\/\/flcube.com\/?p=59971","name":"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-19T06:07:01+00:00","description":"Viva Biotech Holdings (HKG: 1873) has entered into a strategic partnership with NVIDIA Corporation (NASDAQ: NVDA) to optimize the Proteina Complexa model, advancing AI\u2011driven design of mini\u2011binders targeting ActRIIA \u2013 a collaboration showcasing Viva Bio's integrated \"dry lab\u2011wet lab closed\u2011loop\" R&D platform at the intersection of computational biology and high\u2011throughput protein engineering.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59971#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59971"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59971#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Viva Biotech Partners with NVIDIA to Optimize AI Drug Design \u2013 Proteina Complexa Model Targets ActRIIA Mini\u2011Binders"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59971"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59971\/revisions"}],"predecessor-version":[{"id":59972,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59971\/revisions\/59972"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}